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Abstract
Objective: This study intends to define the role of primary surgery for 
patients with resectable stage III/IV tonsillar carcinoma.
Materials and Methods: From 1987 to 2004, 82 patients with resectable 
stage III/IV tonsillar carcinoma were treated curatively with surgery plus 
radiotherapy (n = 22), concurrent chemoradiotherapy (n = 25), or radiother-
apy alone (n = 35). We compared surgery plus radiotherapy with concurrent 
chemoradiotherapy and radiotherapy alone. The primary endpoint was 
5-year overall survival.
Results: The median follow-up time was 39 months (range, 1–216 months). 
All living patients were followed-up for at least 2 years. The 5-year overall 
survival for surgery plus radiotherapy was similar to that of concurrent 
chemoradiotherapy (52.9% vs. 58.9%; hazard ratio [HR], 1.46; 95% con-
fidence interval [CI], 0.71–3.01; p = 0.31) and radiotherapy alone (52.9% 
vs. 45.7%; HR, 0.87; 95% CI, 0.47–1.62; p = 0.66). For 5-year local con-
trol, surgery plus radiotherapy was better than radiotherapy alone (68.1% 
vs. 42.8%; HR, 0.39; 95% CI, 0.16–0.98; p = 0.045). T4 disease resulted 
in poorer local control than T1–3 disease (HR, 5.89; 95% CI, 2.36–14.70; 
p < 0.0001). After multivariate analysis, treatment modality had a consistent 
statistically insignificant impact on all clinical outcomes of interest.
Conclusion: For patients with resectable stage III/IV tonsillar carcinoma, 
surgery plus radiotherapy is comparable to concurrent chemoradiotherapy 
and results in better local control than radiotherapy alone. Current evidence 
is still insufficient to definitively recommend replacing primary surgery with 
nonsurgical treatment modalities. [Tzu Chi Med J 2008;20(1):49–57]
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1. Introduction
For patients with resectable and locoregionally ad-
vanced stage III/IV tonsillar carcinoma, two main types 
of primary therapy are available: primary surgery and 
nonsurgical treatment modalities. Two randomized tri-
als have compared primary surgery with nonsurgical 
treatment modalities: the Radiation Therapy Oncology 
Group (RTOG) 70-03 study compared surgery (S) with 
radiotherapy (RT), and another trial compared surgery 
plus radiotherapy (S + RT) with concurrent chemora-
diotherapy (CCRT) [1,2]. Although both trials showed 
comparable outcomes between primary surgery and 
nonsurgical treatment modalities, inadequate study 
power, mainly due to practice difficulty, prevented 
researchers from drawing definitive conclusions for 
patients in this subgroup. In addition, non-randomized 
studies have shown diverse results. In a large retro-
spective study of 384 patients with tonsillar carcinoma, 
S + RT demonstrated better tumor control than RT 
alone [3]. A meta-analysis that incorporated 51 reported 
series, however, did not confirm the benefits of sur-
gery ± RT compared with RT ± neck dissection [4].
More evidence is needed to determine whether non-
surgical treatment modalities are as good as primary 
surgery for patients with resectable stage III/IV tonsil-
lar carcinoma. As a result, in daily practice, although 
CCRT with deferred surgery is the preferred treatment 
in many institutions, including ours, primary surgery 
is still the treatment of choice in others [5]. The best 
way to answer this issue is with a well-controlled trial 
with a randomized design. However, randomly compar-
ing patients in a trial has significant practice difficul-
ties; small case numbers and slow allocation often 
result in inadequate study power. Hence, further ran-
domized trials with adequate power to well define 
this issue seem unlikely [1,2]. For this reason, we con-
ducted this retrospective study and tried to further 
extend the evidence line for this issue.
This study intended to define the role of primary 
surgery for patients with resectable stage III/IV ton-
sillar carcinoma; S + RT was compared with nonsur-
gical treatment modalities, either CCRT or RT alone. 
Analysis of failure patterns, potential prognostic factors, 
and RT-related toxicities were also explored.
2. Materials and methods
2.1. Study design and endpoints
This case series retrospectively compared S + RT with 
nonsurgical treatment modalities, either CCRT or RT 
alone. The null hypothesis stated that no significant 
differences exist between the S + RT and the other 
two groups at the primary endpoint, namely 5-year 
overall survival. The alternative hypothesis, therefore, 
was that significant survival differences exist between 
groups on either side. Secondary endpoints were: 
disease-free survival, locoregional control, local con-
trol, distant metastasis-free survival, and disease-
specific survival.
2.2. Patient population and data 
collection
From January 1987 to December 2004, 141 patients 
with histologically proven tonsillar malignancy were 
treated at one institution, Tri-Service General Hospital. 
We excluded 59 patients and included the remaining 
82 patients with resectable stage III/IV squamous cell 
or undifferentiated carcinoma of the tonsil, as shown 
in Fig. 1. All patients were staged in accordance with 
the 2002 American Joint Committee on Cancer stag-
ing system [6]. According to the staging criteria, T4 
disease was subdivided into resectable T4a and unre-
sectable T4b disease. This study excluded patients 
with unresectable T4b disease. Resectable stage III/
IV disease, therefore, was defined as stage III (T3 N0–1, 
T1–2 N1), stage IVA (T4a N0–2, T1–3 N2), or non-T4b stage 
IVB (T1–4a N3).
For all patients, we reviewed data from the can-
cer registry database and all original medical charts. 
Discrepancies were resolved by consensus. Head and 
neck cross-sectional images, computed tomography, 
magnetic resonance imaging, or both, were used for 
staging in all patients. Table 1 shows similar pre-
treatment characteristics for patients in all groups. 
No patient was lost to follow-up. All patients were 
followed-up in the radiation oncology department of 
Tri-Service General Hospital. Follow-up time intervals 
were every 1–3 months during the first year after com-
pletion of RT, every 3–6 months during the second 
to fifth year, and every 6–12 months thereafter.
2.3. Treatment modality and policy
All patients were treated curatively with one of the 
following treatment modalities: S + RT (n = 22), CCRT 
(n = 25), or RT alone (n = 35). There was no formal 
treatment policy during the time span of this study. 
In general, primary surgery was performed less often 
than the other two organ-preserving treatments with 
a surgical rate of 26.8% (22/82). Whether primary 
surgery or a nonsurgical modality was actually con-
ducted depended on the patient’s age, associated 
comorbidities, physician’s preference and, more impor-
tantly, patient choice. All patients treated surgically 
received wide excision via a mandibulotomy approach 
with or without flap reconstruction. No surgery via 
the intra-oral route was performed. Thirteen patients 
with neck surgery received an ipsilateral modified 
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Tonsillar malignancies treated
(n = 141) 
Excluded (n = 59)  
• Non-Hodgkin’s lymphoma (n = 21)
• Soft tissue sarcoma (n = 2)  
• Unresectable T4b disease (n = 26)
• Stage I through II (n = 7)
• Pretreatment M1 disease (n = 3)
Included (n = 82)
• Previously untreated
• Squamous cell or undifferentiated carcinoma
• Resectable stage III/IV non-metastatic disease 
Lost to follow-up (n = 0)
Analyzed (n = 22) 
Lost to follow-up (n = 0) 
Analyzed (n = 25) 
Lost to follow-up (n = 0)
Analyzed (n = 35) 
S + RT
(n = 22) 
CCRT
(n = 25)
RT alone
(n = 35)
Died before analysis (n = 18)
Disease failure events (n = 10)
Local regional failures (n = 8)
Local failures (n = 6)
Died before analysis (n = 13) 
Disease failure events (n = 12) 
Local regional failures (n = 11) 
Local failures (n = 6)  
Died before analysis (n = 24)
Disease failure events (n = 25)
Local regional failures (n = 22)
Local failures (n = 19)
Fig. 1 — Flow diagram of patients.
Table 1 — Pretreatment patient characteristics by treatment modality
 Patient number (%) p
 S + RT CCRT RT alone Total S + RT vs. CCRT S + RT vs. RT alone
Age     0.25 0.42
  > 50 yr 13 (59.1) 10 (40.0) 16 (45.7) 39 (47.6)
  ≤ 50 yr 9 (40.9) 15 (60.0) 19 (54.3) 43 (52.4)
Gender     0.10 1.00
  Male 19 (86.4) 25 (100) 29 (82.9) 73 (89.0)
  Female 3 (13.6) 0 6 (17.1) 9 (11.0)
T classification     1.00 0.58
  T1–3 15 (68.2) 17 (68.0) 20 (57.1) 52 (63.4)
  T4 7 (31.8) 8 (32.0) 15 (42.9) 30 (36.6)
N classification     0.08 0.55
  N0–1 8 (36.4) 3 (12.0) 9 (25.7) 20 (24.4)
  N2–3 14 (63.6) 22 (88.0) 26 (74.3) 62 (75.6)
Stage     0.17 1.00
  III 4 (18.2) 1 (4.0) 6 (17.1) 11 (13.4)
  IVA/IVB 18 (81.8) 24 (96.0) 29 (82.9) 71 (86.6)
Histology     0.29 0.70
  Grade 1–2 15 (68.2) 12 (48.0) 22 (62.9) 49 (59.8)
  Grade 3–4 7 (31.8) 12 (48.0) 12 (34.3) 31 (37.8)
  NOS 0 1 (4.0) 1 (2.9) 2 (2.4)
  Total (%) 22 (26.8) 25 (30.5) 35 (42.7) 82 (100)
S + RT = surgery plus radiotherapy; CCRT = concurrent chemoradiotherapy; RT alone = radiotherapy alone; NOS = not otherwise specified.
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radical neck dissection and two had a supraomohyoid 
neck dissection.
All patients treated with S + RT had postoperative 
adjuvant RT if any of the following criteria were present: 
(1) primary disease ≥ T3; (2) nodal disease ≥ N1. The 
RT technique used in all patients in the three groups 
was the same. Conventional RT with bilateral opposed 
cone-down portals encompassed the primary tumor 
and bilateral upper neck. The median dose for post-
operative RT was 64.8 (range, 54.0–66.8 Gy). In the 
CCRT and RT alone groups, a median dose of 72 Gy 
(range, 64.8–78.8 Gy) was given for gross disease. 
No brachytherapy or intra-oral cone boost was used. 
A dose of 45–50 s delivered from the lower neck 
down to the supraclavicular fossae. Cisplatin alone 
was given concurrently with RT for patients treated 
with CCRT. We classified normal tissue RT-related side 
effects according to the RTOG criteria for radiation 
morbidity [7].
2.4. Definition of endpoints
Overall survival was defined as the time interval 
from the date of completion of RT to the date of death 
from any cause. Disease-free survival was defined 
as the time interval from the date of completion of 
RT to the date of disease failure at any site, or death. 
Locoregional failure was defined as locoregional 
residual disease 1 month after completion of RT, as 
shown by clinical or pathological evidence, or loco-
regional recurrence after an interval in which the 
patient was free of locoregional disease. Local fail-
ure was defined the same way as locoregional failure. 
Successful salvage was defined as a disease-free inter-
val of at least 1 year after salvage management for 
r-M0 recurrence.
2.5. Statistical analysis
Survival and control rates were estimated cumulatively 
using the Kaplan-Meier method. A curve difference 
between groups was assessed by the log-rank test. 
Fisher’s exact test was used for assessing differen-
ces in binary variables. For estimating effect size, 
the hazard ratio (HR) was provided with a 95% con-
fidence interval (CI) in addition to the conventional 
p value.
Multivariate analyses were performed using the Cox 
proportional hazards regression method. For multi-
variate analysis, the independent factors of age (≤ 50 
years vs. > 50 years), gender (male vs. female), T clas-
sification (T1–2 vs. T3–4), N classification (N0–1 vs. 
N2–3), and histology (Grade 1–2 vs. 3–4) were put 
together to analyze all outcomes of interest between 
groups. All tests were two-tailed and considered to 
be statistically significant if p was less than 0.05.
3. Results
3.1. Patients and tumors
The median follow-up time for all patients was 39 
months (range, 1–216 months). At the time of analy-
sis, 27 patients were still alive. All living patients were 
followed-up for at least 2 years with a median follow-
up time of 63 months (range, 25–216 months). This 
study included 73 men and nine women, with a median 
age of 50 years (range, 20–81 years). We observed 
41 lesions on the right tonsil and 37 lesions on the 
left. Four patients (4.9%) had bilateral tonsillar pri-
mary lesions. At presentation, 73 (89.0%) patients 
had clinical neck node involvement, and eight of 73 
(11.0%) patients had nodal disease in the contralat-
eral side of the neck. By T classification, rates of con-
tralateral side nodal involvement were 2.9% (1/35) 
for T1–2 and 14.9% (7/47) for T3–4 disease.
3.2. Primary endpoint assessment
There were no statistically significant differences 
in the primary endpoint of 5-year overall survival 
between groups as follows: 52.9% in the S + RT group 
versus 58.9% in the CCRT group (HR, 1.46; 95% CI, 
0.71–3.01; p = 0.31); 52.9% in the S+RT group ver-
sus 45.7% in the RT alone group (HR, 0.87; 95% CI, 
0.47–1.62; p = 0.66) (Fig. 2, Table 2).
3.3. Secondary endpoints assessment
Table 2 shows bizarre results when comparing S + RT 
with CCRT but shows better local control for S + RT 
than for RT alone; there was less impact, in order, 
from local control through locoregional control to 
disease-free survival when S + RT was compared with 
RT alone. For all patients, we observed 47 disease 
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Fig. 2 — Kaplan-Meier estimates of overall survival accord-
ing to treatment modality.
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failures, 41 locoregional failures, and 31 local fail-
ures (Fig. 1). There were statistically insignificant dif-
ferences between the S + RT and the other two groups 
with regard to 5-year disease-free survival (Fig. 3A).
For locoregional control, the median time to locore-
gional failure was 11 months (range: 1–59 months), 
and 78.1% (32/41) occurred within the first 2 years 
after completion of RT. Patients in the S + RT group 
showed similar locoregional control to those in the 
CCRT group. Although there was no statistically sig-
nificant difference between S + RT and RT alone, we 
found a statistical trend (HR, 0.45; 95% CI, 0.20–
1.01; p = 0.053; Fig. 3B). In addition, we observed no 
contralateral neck nodal failure in any patient.
For local control, the median time to local failure 
was 11 months (range: 1–59 months), and 80.6% 
(25/31) occurred within the first 2 years after com-
pletion of RT. Patients in the S + RT group had local 
control similar to those in the CCRT group but dem-
onstrated a better local control rate than those in the 
RT alone group, with 68.1% for S + RT and 42.8% for 
RT alone (HR, 0.39; 95% CI, 0.16–0.98; p = 0.045; 
Fig. 3C). The rates for 5-year local control by T clas-
sification were as follows: T1, 66.7%; T2, 79.9%; T3, 
73.0%; and T4, 27.5%. Because of similar local con-
trol results for the T1, T2 and T3 classifications, we 
grouped patients into T1–3 and T4, showing a highly 
significant statistical difference (p < 0.0001; Fig. 4).
3.4. Failure pattern and salvage management
For all patients, the main type of disease failure was 
isolated r-M0 locoregional failure (35/47, 74.5%). Of 
these, 20 of 35 patients (57.1%) had salvage manage-
ment for their recurrent disease, but the successful 
salvage rate was only 35% (7/20). Successful salvage 
rates by treatment modality were: S + RT, 50.0% (2/4); 
CCRT, 28.6% (2/7); and RT alone, 33% (3/9). For 
patients with r-M1 disease failure, the lung (8.5%, 
7/82), bone (7.3%, 6/82) and liver (4.9%, 4/82) were 
the most common sites of distant metastases.
3.5. Prognostic factors
In univariate analysis, treatment modality had a sta-
tistically non-significant impact on overall survival, 
disease-free survival, and locoregional control. For 
local control, S + RT failed to show a statistically signif-
icant impact when compared with CCRT, but demon-
strated a statistically significant difference compared 
with RT alone. In addition, T4 disease was the pre-
dictive factor affecting local control when compared 
with T1–3 disease (HR, 5.23; 95% CI, 2.45–11.15; 
p < 0.0001).
After multivariate analysis, treatment modality 
consistently failed to show a statistically significant 
impact on all clinical outcomes, in terms of over-
all survival (p = 0.11), disease-free survival (p = 0.93), 
locoregional control (p = 0.59), local control (p = 
0.74), distant metastasis-free survival (p  = 0.83), and 
disease-specific survival (p = 0.45). For all multivari-
ate analyses, only T classification, T4 versus T1–3, 
showed a statistically significant impact on both over-
all survival (HR, 2.64; 95% CI, 1.37–5.09; p = 0.004) 
and local control (HR, 5.89; 95% CI, 2.36–14.70; 
p < 0.0001).
Table 2 — Five-year clinical outcomes by treatment modality
Outcomes (%)
 S + RT vs. CCRT
 S + RT CCRT HR 95% CI p
Overall survival 52.9 58.9 1.46 0.71–3.01 0.31
Disease free survival 53.7 48.0 0.82 0.35–1.89 0.63
Locoregional control  59.2 51.0 0.72 0.29–1.78 0.47
Local control 68.1 71.4 1.11 0.36–3.45 0.86
DM-free survival  90.7 82.2 0.67 0.11–3.99 0.66
Disease-specific survival 62.9 65.4 1.10 0.41–2.95 0.84
Outcomes (%)
 S + RT vs. RT alone
 S + RT RT HR 95% CI p
Overall survival 52.9 45.7 0.87 0.47–1.62 0.66
Disease free survival 53.7 36.7 0.52 0.25–1.09 0.09
Locoregional control  59.2 36.7 0.45 0.20–1.01 0.053
Local control 68.1 42.8 0.39 0.16–0.98 0.045
DM-free survival  90.7 87.3 0.44 0.09–2.15 0.31
Disease-specific survival 62.9 48.6 0.55 0.24–1.25 0.15
S + RT = surgery plus radiotherapy; CCRT = concurrent chemoradiotherapy; RT = radiotherapy; HR = hazard ratio; CI = confidence interval; DM = distant 
metastasis.
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3.6. Toxicities
No statistically significant differences were found 
between groups with regard to RT-related toxicities 
(Table 3). After head and neck irradiation, the most 
common acute and late toxicity were radiation 
mucositis and dry mouth, respectively. Four surgical 
patients had postoperative complications requiring 
a second surgical intervention, including osteoradio-
necrosis (n = 1), poor wound healing (n = 2), and per-
sistent fistula (n = 1), for a complication rate of 18.2% 
(4/22). Four patients had post-RT osteoradionecrosis 
(4.9%, 4/82), which was successfully treated with 
surgical intervention.
4. Discussion
This study showed statistically non-significant differ-
ences in 5-year overall survival for S + RT compared with 
CCRT and RT alone; thus, the null hypothesis could 
not be rejected. For patients with resectable stage III/
IV tonsillar carcinoma, nonsurgical treatment modali-
ties, including CCRT, should not yet definitively replace 
S + RT, despite the current trend for organ preservation. 
In addition, S + RT showed better local control than 
RT alone, even though this benefit translated poorly 
into locoregional control, disease-free survival and, 
finally, overall survival. For overall survival, T classifi-
cation (T4 vs. T1–3) was the only independent factor.
S + RT vs. CCRT, p = 0.63
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Fig. 3 — Kaplan-Meier estimates, according to treatment modality, of: (A) disease-free survival; (B) locoregional control; 
(C) local control.
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Table 3 — Radiotherapy-associated toxicities by treatment modality
Toxicity
 Treatment modality p
 S + RT CCRT RT alone S + RT vs. CCRT S + RT vs. RT alone
Grade 3–4 mucositis, n (%) 12 (54.5) 20 (80.0) 20 (71.4) 0.12 0.26
Late dry mouth
  All grades, n (%) 17 (77.3) 20 (80.0) 32 (91.4) 1.00 0.24
  Mean grade 3.0 3.4 3.6 0.46 0.23
Neck fibrosis
  All grades, n (%) 12 (54.5)  8 (32.0) 16 (45.7) 0.15 0.59
  Mean grade 2.4 1.9 1.8 0.54 0.18
Osteoradionecrosis, n (%) 1 (4.5) 1 (4.0) 2 (5.7) 1.00 1.00
S + RT = surgery plus radiotherapy; CCRT = concurrent chemoradiotherapy; RT alone = radiotherapy alone.
For patients with resectable stage III/IV tonsil-
lar carcinoma, CCRT is preferred to S + RT for organ 
preservation in many institutions including ours, but 
S + RT remains the treatment of choice for operable 
patients in other hospitals [5]. This phenomenon shows 
that there is still no definitive conclusion for com-
paring primary surgery with nonsurgical treatment 
modalities (Table 4). Only one randomized trial that 
compared CCRT with S + RT has been conducted and 
it showed no significant difference in 3-year disease-
free survival [2]. In addition, a retrospective study 
reported comparable overall survival and freedom 
from disease relapse between primary surgery and 
RT in conjunction with or without chemotherapy [8]. 
Other evidence from one-treatment-arm studies of 
either S + RT or CCRT, however, seemed to show that 
patients treated with S + RT had a better 5-year local 
control rate than those treated with CCRT, being 
68–71% and 48–59%, respectively (Table 4) [9–15]. 
Interpreting data from these studies this way should 
be done with caution. Nearly all patients treated in 
S + RT series had resectable disease, but a significant 
proportion of those treated in CCRT series had unre-
sectable disease, which inevitably presents more dis-
ease burden and poorer clinical results than that of 
resectable disease. Our study, which excluded patients 
with unresectable disease, showed comparable out-
comes between S + RT and CCRT. This observation is 
similar to that in a prior randomized trial [2]. Despite 
the retrospective nature, our study may further extend 
the evidence line for this issue.
Uncontrolled local disease is still a significant 
treatment challenge in T4 tonsillar carcinoma, regard-
less of treatment modality. In this study, T3 disease 
Table 4 — Studies of S + RT, CCRT, or both, for stage III/IV tonsillar carcinoma
First author Treatment n
 Outcomes, % (yr) Fatal
[Reference]   OS DFS LRC LC toxicity, n
Soo [2]* S + RT 60 50% (3) 54% (3) 75% (3) 77% (3) 0
 CCRT 59 40% (3) 43% (3) 68% (3) 80% (3) 0
 p  0.55 0.43 NR NR NR
Shirazi [8] S + RT 38 71% (4) 67% (4) 87%† (4) 94% (4) 0
 CCRT 17 48% (4) 53% (4) 92%† (4) 86% (4) 0
 p  0.27 0.39 0.58 0.29 NR
This study S + RT 22 52.9% (5) 53.7% (5) 59.2% (5) 68.1% (5) 0
 CCRT 25 58.9% (5) 48.0% (5) 51.0% (5) 71.4% (5) 0
 p  0.31 0.63 0.47 0.86 NR
Perez [3] S + RT 86 NR 30–62% (5) NR 68% (5) 2
Laccourreye [9] S + RT 51 NR NR NR 83% (5) 0
Foote [10] S + RT 16 78–100% (5) NR 69% (5) 71% (5) 0
Denis [11]* CCRT 109 22% (5) 27% (5) 48% (5) 59% (5) 1
Fallai [12]* CCRT 64 40% (5) 36% (5) 48% (5) NR 3
Jeremic [13]* CCRT 106 29–32% (5) NR 72–74%† (5) 48–51% (5) 0
Brizel [14]* CCRT 56 55% (3) 61% (3) 70% (3) 71% (3) 1
Vokes [15] CCRT 76 55% (3) 72% (3) 92% (3) NR 0
*Randomized clinical trial; †regional control rate. OS = overall survival; DFS = disease-free survival; LRC = locoregional control; LC = local control; 
S + RT = surgery plus radiotherapy; CCRT = concurrent chemoradiotherapy; NR = not reported.
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was similar to T1–2 in local control, and T4 tumors 
showed poorer local control than T1–3 tumors (HR, 
5.89; 95% CI, 2.36–14.70; p < 0.0001). More effec-
tive treatment is still needed in addition to primary 
surgery for patients with T4 disease. Although more 
severe adverse effects, including lethal toxicities, were 
reported, S + CCRT demonstrated better locoregional 
control, disease-free survival and overall survival than 
S + RT in two well-controlled randomized trials [16,17]. 
As a result, S + CCRT should be the priority for high-risk 
and medically suitable patients with primary surgery 
as their chosen treatment plan, especially for those 
with T4 disease.
For locoregionally advanced tonsillar carcinoma, 
CCRT is more effective than RT alone for organ pres-
ervation with a cost of more acute but not late tox-
icity [11,14]. Hence, current treatment guidelines 
recommend CCRT as the treatment of choice and 
reserves RT alone for those unsuited to chemo-
therapy [18]. Conventionally, RT alone with 70 Gy in 
35 fractions given to the mid-plane has been con-
sidered curative for patients with locoregionally 
advanced disease, and has been widely adopted 
in several randomized trials as the active control 
[11–13]. Our analysis, however, suggests that this 
conventional 70 Gy fractionation is insufficient for 
T4 tonsillar carcinoma. For patients with T4 disease, 
a higher RT dose should be seriously considered. 
Intensity-modulated radiotherapy (IMRT) has shown 
a potential role for safely escalating the RT dose 
without significantly increasing acute or late toxicity 
[19]. Concurrent chemotherapy-IMRT with an RT 
dose greater than 70 Gy could be a choice for better 
organ preservation than conventional CCRT.
A meta-analysis showed that neoadjuvant chemo-
therapy followed by definitive RT had no additional 
benefits over RT alone for bulky primary tumors [20]. 
Recently, a phase II study tested the role of induc-
tion chemotherapy followed by CCRT, and reported 
high complete response and three-year overall sur-
vival rates, namely 90% and 70%, respectively [21]. 
But another phase II trial showed excess acute tox-
icities for this aggressive combination [22]. Whether 
this multimodal treatment is useful or harmful may 
be tested with caution in the context of phase III 
randomized trials with careful toxicity monitoring. A 
promising agent of targeted therapy, a monoclonal 
antibody against the epidermal growth factor recep-
tor, has shown encouraging results when applied con-
currently with definitive RT [23]. This combination 
resulted in better locoregional control and less disease-
related mortality without increasing acute toxicity 
than RT alone, especially for patients with oropharynx 
cancers. For patients with locoregionally advanced 
tonsillar carcinoma, further investigation of chemo-
therapy and IMRT applied concurrently with targeted 
therapy may be of great value.
A previous study has shown that prior surgery or 
teeth extraction before RT is a predisposing factor 
for mandible osteoradionecrosis [24]. In our study, 
patients treated surgically showed a rate of osteo-
radionecrosis similar to those seen in nonsurgically 
treated patients. This study also confirmed that CCRT 
did not increase RT-related late sequelae [11]. Four 
out of 22 surgical patients (18.2%) developed severe 
complications requiring a second surgical interven-
tion. Postoperative swallow and speech morbidities 
are important for the quality of life of patients treated 
surgically. This study, however, had incomplete data 
on these morbidities. These morbidity data should 
be routinely and prospectively measured in future 
surgical studies.
This study has several limitations, including the 
retrospective study nature and small case number. 
Inevitably, a retrospective study design has some 
degree of selection bias and, therefore, a lower study 
power than that of randomized trials [1,2]. On the 
other hand, the small case number increases the proba-
bility of false-negative interpretation. These two main 
factors decrease the study efficacy. But we would like 
to emphasize that definitive conclusions for compar-
ing surgery with nonsurgical treatment modalities 
are still unavailable, and practice difficulty prevents 
further randomized trials with adequate statistical 
power from addressing this issue.
S + RT is comparable to CCRT and shows better 
local control than RT alone for resectable stage III/
IV tonsillar carcinoma. In terms of cancer disease 
control, despite a trend toward organ preservation, 
current evidence is still insufficient to definitively rec-
ommend replacing primary surgery with nonsurgical 
treatment modalities.
References
 1. Kramer S, Gelber RD, Snow JB, et al. Combined radia-
tion therapy and surgery in the management of advanced 
head and neck cancer: final report of study 73-03 of 
the Radiation Therapy Oncology Group. Head Neck Surg 
1987;10:19–30.
 2. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radio-
therapy versus concurrent chemoradiotherapy in stage 
III/IV squamous cell head and neck cancer: a randomized 
comparison. Br J Cancer 2005;93:279–86.
 3. Perez CA, Patel MM, Chao KSC, et al. Carcinoma of the 
tonsillar fossa: prognostic factors and long-term ther-
apy outcome. Int J Radiat Oncol Biol Phys 1998;42:
1077–84.
 4. Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous 
cell carcinoma of the oropharynx: surgery, radiation ther-
apy, or both. Cancer 2002;94:2967–80.
 5. Poulsen M, Porceddu SV, Kingslev PA, Tripcony L, 
Coman W. Locally advanced tonsillar squamous cell carci-
noma: treatment approach revisited. Larynoscope 2007;
117:45–50.
 TZU CHI MED J  March 2008  Vol 20  No 1 57
 6. Greene FL, Page DL, Fleming ID, et al. American Joint Com-
mittee on Cancer (AJCC). Manual for Staging of Cancer, 
6th edition. New York: Springer-Verlag, 2002:33–45.
 7. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation 
Therapy Oncology Group (RTOG) and The European 
  Organization for Research and Treatment of Cancer (EORTC). 
Int J Radiat Oncol Biol Phys 1995;31:1341–6.
 8. Shirazi HA, Sivanandan R, Goode R, et al. Advanced-stage 
tonsillar squamous carcinoma: organ preservation versus 
surgical management of the primary site. Head Neck 2006;
28:587–94.
 9. Laccourreye O, Hans S, Menard M, Garcia D, Brasnu D, 
Holsinger FC. Transoral lateral oropharyngectomy for squa-
mous cell carcinoma of the tonsillar region: II. An analy-
sis of the incidence, related variables, and consequences 
of local recurrence. Arch Otolaryngol Head Neck Surg 
2005;131:592–9.
10. Foote RL, Schild SE, Thompson WM, et al. Tonsil cancer: 
patterns of failure after surgery alone and surgery combined 
with postoperative radiation therapy. Cancer 1994;73:
2638–47.
11. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T. 
Final results of the 94-01 French Head and Neck Oncology 
and Radiotherapy Group randomized trial comparing radio-
therapy alone with concomitant radiochemotherapy in 
advanced-stage oropharynx carcinoma. J Clin Oncol 2004;
22:69–76.
12. Fallai C, Bolner A, Signor M, et al. Long-term results of 
conventional radiotherapy versus accelerated hyperfrac-
tionated radiotherapy versus concomitant radiotherapy 
and chemotherapy in locoregionally advanced carcinoma 
of the oropharynx. Tumori 2006;92:41–54.
13. Jeremic B, Yuta S, Stanisavljevic B, Milojevic L, Milicic B, 
Nikolic N. Radiation therapy alone or with concurrent low-
dose daily either cisplatin or carboplatin in locally advanced 
unresectable squamous cell carcinoma of the head and 
neck: a prospective randomized trial. Radiother Oncol 
1997;43:29–37.
14. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated 
irradiation with or without concurrent chemotherapy for 
locally advanced head and neck cancer. N Engl J Med 
1998;338:1798–804.
15. Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, 
Humerickhouse R. Concomitant chemoradiotherapy as 
primary therapy for locoregionally advanced head and 
neck cancer. J Clin Oncol 2000;18:1652–61.
16. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative 
concurrent radiotherapy and chemotherapy for high-risk 
squamous-cell carcinoma of the head and neck. N Engl J 
Med 2004;350:1937–44.
17. Bernier J, Domenge C, Ozsahin M, et al. Postoperative 
irradiation with or without concomitant chemotherapy for 
locally advanced head and neck cancer. N Engl J Med 
2004;350:1945–52.
18. National Comprehensive Cancer Network. National Com-
prehensive Cancer Network Clinical Practice Guidelines 
in Oncology: Head and Neck Cancers, Version 1. 
2007. Available from http://www.nccn.org/professionals/
physician_gls/PDF/head–and–neck.pdf [Date accessed: 
June 13, 2007]
19. Yao M, Dornfeld KJ, Buatti JM, et al. Intensity-modulated 
radiation treatment for head-and-neck squamous cell 
carcinoma—the University of Iowa experience. Int J Radiat 
Oncol Biol Phys 2005;63:410–21.
20. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy 
added to locoregional treatment for head and neck 
squamous-cell carcinoma: three meta-analyses of updated 
individual data. MACH-NC Collaborative Group. Meta-Analysis 
of Chemotherapy on Head and Neck Cancer. Lancet 2000;
355:949–55.
21. Machtay M, Rosenthal DI, Hershock D, et al. Organ preser-
vation therapy using induction plus concurrent chemora-
diation for advanced resectable oropharyngeal carcinoma: 
a University of Pennsylvania phase II trial. J Clin Oncol 
2002;20:3964–71.
22. Mantovani G, Proto E, Massa E, et al. Induction chemo-
therapy followed by concomitant chemoradiation therapy 
in advanced head and neck cancer: a phase II study for 
organ-sparing purposes evaluating feasibility, effective-
ness and toxicity. Int J Oncol 2002;20:419–27.
23. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus 
cetuximab for squamous cell carcinoma of the head and 
neck. N Engl J Med 2006;354:567–78.
24. Reuther T, Schuster T, Mende U, Kubler A. Osteoradio-
necrosis of the jaws as a side effect of radiotherapy of 
head and neck tumour patients—a report of a thirty year 
retrospective review. Int J Oral Maxillofac Surg 2003;
32:289–95.
